Download Files:
TTA-A2
$180 – $3,250
Products Details
Product Description
– TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy[1][2].
Web ID
– HY-111828
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C20H21F3N2O2
References
– [1]Thomas S Reger, et al.Pyridyl amides as potent inhibitors of T-type|[2]Richard L Kraus, et al.In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther. 2010 Nov;335(2):409-17.
CAS Number
– 953778-63-7
Molecular Weight
– 378.39
Compound Purity
– 99.0
SMILES
– O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C3CC3)C=C2
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Calcium Channel
Isoform
– T-type calcium channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
